Company Overview of Breckenridge Pharmaceutical, Inc.
Breckenridge Pharmaceutical, Inc. engages in the research, development, marketing, and distribution of generic prescription products in various therapeutic categories. The company markets its generic prescription products in various dosage forms, including tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, and powders, as well as focuses on the provision of injectables, transdermals, inhalers, and topicals. It also provides various medical foods for the dietary management of patients with therapeutic or chronic medical needs; and prenatal and dietary supplements. In addition, the company handles various aspects of business operations, including procurement...
6111 Broken Sound Parkway NW
Boca Raton, FL 33487
Founded in 1983
Key Executives for Breckenridge Pharmaceutical, Inc.
Executive Director of Operations
Senior Vice President of Sales & Marketing-New Jersey Office
Vice President of Finance for CT Office
Associate Director of Technical Services for CT Office
Compensation as of Fiscal Year 2016.
Breckenridge Pharmaceutical, Inc. Key Developments
Breckenridge Launches Armodafinil Tablets with its Partner Natco Pharma Limited
Nov 28 16
Breckenridge Pharmaceutical, Inc. announced that it has launched its ANDA for Armodafinil tablets (CIV) in 50mg, 150mg and 250mg strengths on November 28, 2016, after having received final approval by FDA. Armodafinil tablets is a generic version of Nuvigil® by Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. Breckenridge and Cephalon entered into a confidential settlement which includes a license to market its ANDA effective 180 days after the initial launch of generic versions of Nuvigil®. Breckenridge is launching Armodafinil tablets with its partner Natco Pharma Limited, who is owner of the ANDA. Breckenridge's Armodafinil tablets are AB-rated to Nuvigil®, a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD).
Breckenridge Announces Entry into Injectable Market with the Immediate Launch of Methylergonovine Maleate Injection
Nov 9 16
Breckenridge Pharmaceutical, Inc. announced the immediate launch of Methylergonovine Maleate Injection, USP 0.2mg/mL. This product is an AP rated generic to Methergin®, a product owned by Edison Therapeutics, LLC. and is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage. Breckenridge is launching this product in conjunction with the ANDA holder, Ergoject, LLC. This launch is the first of several planned injectable products the company plans to launch in the near future and showcases the investment the company made in hiring David Giering, Director, Institutional Sales and Trade Relations, over a year ago. David brings more than 15 years of experience in the pharmaceutical industry, including branded institutional sales, wholesaler category management, and most recently with a major generic pharmaceutical company, managing its injectable portfolio.
Breckenridge Pharmaceutical Reports Final ANDA Approval for Lacosamide Tablets
May 6 16
Breckenridge Pharmaceutical reported that Breckenridge and MSN Laboratories were granted final approval for their ANDA lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg. a generic version of Vimpat by UCB Pharma. Breckenridge and MSN filed their Paragraph IV ANDA on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|